




Edition: BP 2025 (Ph. Eur. 11.6 update)

Terconazole



[General Notices](#)

(Ph. Eur. monograph 1270)



$C_{26}H_{31}Cl_2N_5O_3$ 532.5 67915-31-5

Action and use

Antifungal.

Ph Eur

DEFINITION

1-[4-[[[(2*RS*,4*SR*)-2-(2,4-Dichlorophenyl)-2-[(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)piperazine.

Content

99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance

White or almost white powder.

Solubility

Practically insoluble in water, freely soluble in methylene chloride, soluble in acetone, sparingly soluble in ethanol (96 per cent).

It shows polymorphism ([5.9](#)).

IDENTIFICATION

First identification: A.

Second identification: B, C.

A. Infrared absorption spectrophotometry ([2.2.24](#)).

Comparison [terconazole CRS](#).

If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in the minimum volume of [acetone R](#), evaporate to dryness in a current of air and record new spectra using the residues.

B. Thin-layer chromatography ([2.2.27](#)).

Test solution Dissolve 30 mg of the substance to be examined in [methanol R](#) and dilute to 5 mL with the same solvent.

Reference solution (a) Dissolve 30 mg of [terconazole CRS](#) in [methanol R](#) and dilute to 5 mL with the same solvent.

Reference solution (b) Dissolve 30 mg of [ketoconazole CRS](#) and 30 mg of [terconazole CRS](#) in [methanol R](#) and dilute to 5 mL with the same solvent.

Plate [TLC octadecylsilyl silica gel plate R](#).

Mobile phase [ammonium acetate solution R](#), [dioxan R](#), [methanol R](#) (20:40:40 V/V/V).

Application 5 µL.

Development In an unsaturated tank over half of the plate.

Drying In a current of warm air for 15 min.

Detection Expose to iodine vapour until the spots appear and examine in daylight.

System suitability Reference solution (b):

— the chromatogram shows 2 clearly separated spots.

Results The principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with reference solution (a).

C. To 30 mg in a porcelain crucible add 0.3 g of [anhydrous sodium carbonate R](#). Heat over an open flame for 10 min. Allow to cool. Take up the residue with 5 mL of [dilute nitric acid R](#) and filter. To 1 mL of the filtrate add 1 mL of [water R](#). The solution gives reaction (a) of chlorides ([2.3.1](#)).

TESTS

Optical rotation ([2.2.7](#))

-0.10° to + 0.10°.

Dissolve 1.0 g in [methylene chloride R](#) and dilute to 10 mL with the same solvent.

Related substances

Liquid chromatography ([2.2.29](#)).

Test solution Dissolve 0.100 g of the substance to be examined in [methanol R](#) and dilute to 10.0 mL with the same solvent.

Reference solution (a) Dissolve 2.0 mg of [ketoconazole CRS](#) and 2.5 mg of [terconazole CRS](#) in [methanol R](#) and dilute to 100.0 mL with the same solvent.

Reference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with [methanol R](#). Dilute 5.0 mL of this solution to 20.0 mL with [methanol R](#).

Column:

— size: $l = 0.1$ m, $\varnothing = 4.6$ mm;

— stationary phase: [base-deactivated octadecylsilyl silica gel for chromatography R](#) (3 µm).

Mobile phase:

— mobile phase A: 3.4 g/L solution of [tetrabutylammonium hydrogen sulfate R](#);

— mobile phase B: [acetonitrile R1](#);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 10	95 → 50	5 → 50
10 - 15	50	50

Flow rate 2 mL/min.

Detection Spectrophotometer at 220 nm.

Injection 10 µL.

Relative retention With reference to terconazole (retention time = about 7.5 min): ketoconazole = about 0.8; impurity A = about 0.85; impurity B = about 0.9.

System suitability Reference solution (a):

— [resolution](#): minimum 13 between the peaks due to ketoconazole and terconazole.

Limits:

— *impurities A, B*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.25 per cent);

— *unspecified impurities*: for each impurity, not more than 0.4 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);

— *total*: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);

— *disregard limit*: 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

[Loss on drying \(2.2.32\)](#)

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

[Sulfated ash \(2.4.14\)](#)

Maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.150 g in 70 mL of a mixture of 1 volume of [anhydrous acetic acid R](#) and 7 volumes of [methyl ethyl ketone R](#). Titrate with [0.1 M perchloric acid](#), determining the end-point potentiometrically at the 2nd point of inflexion ([2.2.20](#)).


1 mL of [0.1 M perchloric acid](#) is equivalent to 17.75 mg of C₂₆H₃₁Cl₂N₅O₃.

STORAGE


Protected from light.

IMPURITIES

Specified impurities A, B.



A. 1-[4-[[[(2*RS*,4*RS*)-2-(2,4-dichlorophenyl)-2-[(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)piperazine,



B. 1-[4-[[[(2*RS*,4*SR*)-2-(2,4-dichlorophenyl)-2-[(4*H*-1,2,4-triazol-4-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)piperazine.

Ph Eur